Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18598342 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | March 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18440895 | Fc VARIANTS WITH ALTERED BINDING TO FcRn | February 2024 | June 2024 | Abandon | 4 | 0 | 0 | No | No |
| 18420507 | SINGLE DOMAIN ANTIBODIES TO INFLUENZA HEMAGGLUTININ A AND B | January 2024 | April 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18542031 | PEPTIDES AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA | December 2023 | December 2024 | Abandon | 12 | 0 | 1 | No | No |
| 18501413 | ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR | November 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18501419 | ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR | November 2023 | June 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18501427 | ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR | November 2023 | July 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18358738 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES | July 2023 | May 2025 | Abandon | 22 | 3 | 1 | No | No |
| 18253999 | METHOD FOR MAXIMIZING CORONAVIRUS KILLING ACTIVITY OF HIGH-DENSITY LIPOPROTEINS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COVID-19 | May 2023 | February 2025 | Allow | 21 | 3 | 1 | No | No |
| 18050216 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES | October 2022 | September 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17934785 | ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2DD8 | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17861920 | AGLYCOSYLATED ANTIBODY Fc REGION FOR TREATING CANCER | July 2022 | February 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17855543 | FUSION PROTEINS COMPRISING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOF | June 2022 | August 2023 | Allow | 13 | 1 | 1 | Yes | No |
| 17804934 | Anti-FcRn Antibodies | June 2022 | February 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17725417 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | April 2022 | May 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17696364 | THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODS | March 2022 | May 2025 | Allow | 38 | 1 | 1 | No | No |
| 17666107 | NOVEL ANTIGEN BINDING MOLECULE FORMATS | February 2022 | July 2024 | Allow | 29 | 3 | 1 | Yes | Yes |
| 17588094 | ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMMUNOGLOBULIN AND USES THEREOF | January 2022 | May 2024 | Allow | 28 | 0 | 0 | Yes | No |
| 17578655 | HUMANIZED ANTI-HUMAN CD19 ANTIBODIES AND METHODS OF USE | January 2022 | September 2024 | Allow | 32 | 1 | 0 | No | No |
| 17569107 | BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20 | January 2022 | May 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17645619 | METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF | December 2021 | December 2024 | Allow | 36 | 2 | 1 | Yes | No |
| 17549706 | Fc VARIANTS WITH ALTERED BINDING TO FcRn | December 2021 | September 2024 | Allow | 33 | 1 | 0 | No | No |
| 17643506 | ANTIBODIES SPECIFIC TO FCRN | December 2021 | September 2024 | Abandon | 34 | 1 | 0 | Yes | No |
| 17534712 | ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASE | November 2021 | April 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17535507 | Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods | November 2021 | September 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17527741 | ENGINEERED Fc CONSTRUCTS | November 2021 | July 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17514824 | HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE | October 2021 | February 2024 | Allow | 28 | 0 | 0 | Yes | No |
| 17491677 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | October 2021 | January 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17408113 | ANTIBODY SPECIFIC FOR CD22 AND METHODS OF USE THEREOF | August 2021 | June 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17400367 | FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONS | August 2021 | May 2024 | Allow | 33 | 0 | 0 | No | No |
| 17304412 | I DOMAIN CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO ICAM-1 | June 2021 | May 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17346648 | ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE | June 2021 | December 2023 | Allow | 30 | 0 | 0 | Yes | No |
| 17324641 | Therapeutic Nuclease Compositions and Methods | May 2021 | January 2025 | Allow | 44 | 1 | 0 | No | No |
| 17288245 | ENGINEERED FC | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17235854 | USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS | April 2021 | June 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17234695 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | April 2021 | November 2023 | Allow | 31 | 0 | 0 | No | No |
| 17228817 | DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | April 2021 | March 2025 | Allow | 47 | 1 | 1 | No | No |
| 17266377 | METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CNS OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE, AND PALMITOYL-PROTEIN THIOESTERASE 1 | February 2021 | June 2025 | Abandon | 53 | 1 | 1 | No | No |
| 17259498 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS | January 2021 | November 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17259480 | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS | January 2021 | September 2024 | Abandon | 44 | 0 | 1 | No | No |
| 17145052 | AGONISTIC ANTIBODIES THAT BIND CD40 | January 2021 | August 2024 | Abandon | 43 | 2 | 1 | No | Yes |
| 17129031 | Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFE | December 2020 | February 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17251316 | ANTIBODY-OLIGONUCLEOTIDE CONJUGATES | December 2020 | January 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 16972840 | ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOF | December 2020 | October 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17107217 | STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAIN | November 2020 | January 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17056385 | FC-EPSILON CAR | November 2020 | June 2025 | Allow | 55 | 4 | 1 | Yes | No |
| 17079299 | Fc VARIANTS WITH ALTERED BINDING TO FcRn | October 2020 | September 2023 | Allow | 35 | 0 | 1 | Yes | No |
| 17049093 | HIGHLY SIALYLATED AUTOANTIBODIES AND USES THEREOF | October 2020 | May 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17035015 | HETERODIMERIC PROTEINS | September 2020 | September 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17029185 | METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS | September 2020 | January 2024 | Abandon | 40 | 1 | 0 | No | No |
| 16981367 | NOVEL ANTI-TIM-3 ANTIBODIES | September 2020 | September 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16997808 | ANTIBODY FC VARIANTS | August 2020 | November 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16990421 | COMPOSITIONS AND METHODS FOR TREATING ANTIBODY RESISTANCE | August 2020 | December 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16967216 | ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR | August 2020 | August 2023 | Allow | 37 | 0 | 1 | Yes | No |
| 16985119 | Fc VARIANTS WITH ALTERED BINDING TO FcRn | August 2020 | October 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16942615 | OPTIMIZED Fc VARIANTS | July 2020 | August 2023 | Allow | 37 | 1 | 1 | No | No |
| 16947021 | STABLE IgG4 ANTIBODIES | July 2020 | June 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16921506 | TRANSFERRIN RECEPTOR-BINDING POLYPEPTIDES AND USES THEREOF | July 2020 | September 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16921154 | ANTIBODY VARIANTS AND USES THEREOF | July 2020 | March 2024 | Allow | 44 | 1 | 1 | No | No |
| 16771377 | Bispecific CD16-Binding Molecules and Their Use in the Treatment of Disease | June 2020 | June 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16883273 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | May 2020 | October 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16839777 | COMBINATIONS AND USES THEREOF | April 2020 | January 2024 | Abandon | 46 | 2 | 1 | No | No |
| 16839903 | COMBINATIONS AND USES THEREOF | April 2020 | February 2024 | Abandon | 47 | 2 | 1 | No | No |
| 16830063 | Fc VARIANTS WITH ALTERED BINDING TO FcRn | March 2020 | March 2024 | Abandon | 47 | 4 | 1 | No | No |
| 16649893 | PROTEINACEOUS HETERODIMER AND USE THEREOF | March 2020 | February 2024 | Allow | 46 | 5 | 1 | Yes | No |
| 16645613 | PROTEINS BINDING NKG2D, CD16, AND C-TYPE LECTIN-LIKE MOLECULE-1 (CLL-1) | March 2020 | May 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16795676 | MODIFIED Fc REGION OF ANTIBODY | February 2020 | November 2024 | Allow | 56 | 3 | 1 | Yes | No |
| 16639150 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | February 2020 | May 2024 | Abandon | 51 | 4 | 1 | Yes | Yes |
| 16631062 | NEW TARGET FOR TREATING CANCER | January 2020 | September 2024 | Abandon | 56 | 0 | 1 | No | No |
| 16628722 | NOVEL THERAPEUTIC ENZYME FUSION PROTEIN AND USE THEREOF | January 2020 | November 2024 | Abandon | 59 | 7 | 1 | Yes | No |
| 16717671 | Antibodies of the Class IGG4 | December 2019 | June 2024 | Allow | 54 | 4 | 1 | Yes | No |
| 16700937 | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR CD19 | December 2019 | April 2023 | Allow | 40 | 1 | 1 | Yes | No |
| 16612867 | ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS | November 2019 | December 2023 | Abandon | 49 | 3 | 2 | Yes | No |
| 16679483 | COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITOR | November 2019 | September 2024 | Allow | 58 | 4 | 0 | Yes | Yes |
| 16590938 | FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | October 2019 | December 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16590143 | HYBRID IMMUNOGLOBULINS WITH MOVING PARTS | October 2019 | May 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16483738 | COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING | August 2019 | December 2023 | Abandon | 52 | 2 | 2 | No | No |
| 16437571 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | June 2019 | November 2023 | Abandon | 53 | 4 | 1 | No | No |
| 16345620 | FC POLYPEPTIDE VARIANTS HAVING AN INCREASED HALF-LIFE | April 2019 | April 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16341437 | COMPOSITIONS AND METHODS FOR NON-MYELOABLATIVE CONDITIONING | April 2019 | June 2025 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 16315356 | FC MUTANTS WITH IMPROVED FUNCTIONAL ACTIVITY | January 2019 | July 2023 | Allow | 54 | 5 | 2 | Yes | No |
| 16213422 | USE OF FCRN ANTAGONISTS FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS | December 2018 | October 2024 | Allow | 60 | 6 | 1 | No | Yes |
| 16017967 | IMMUNOMODULATORY PROTEINS | June 2018 | August 2024 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15742268 | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY | January 2018 | November 2024 | Allow | 60 | 7 | 1 | Yes | No |
| 15741590 | FUSION PROTEINS WHICH BIND TO HUMAN FC RECEPTORS | January 2018 | April 2025 | Abandon | 60 | 8 | 1 | Yes | No |
| 15860163 | HETERODIMERIZED POLYPEPTIDE | January 2018 | April 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 15696138 | HOMOGENEOUS ANTIBODY POPULATIONS | September 2017 | June 2021 | Abandon | 46 | 6 | 1 | Yes | Yes |
| 15667309 | ENGINEERED POLYPEPTIDES AND USES THEREOF | August 2017 | October 2022 | Allow | 60 | 4 | 1 | Yes | No |
| 15616416 | HUMANIZED ANTI-CD22 ANTIBODY | June 2017 | February 2018 | Allow | 8 | 1 | 1 | Yes | No |
| 15263449 | HUMANIZED ANTI-CD22 ANTIBODY | September 2016 | April 2017 | Allow | 7 | 1 | 1 | No | No |
| 15123066 | MULTIMERIC FC PROTEINS | September 2016 | September 2024 | Abandon | 60 | 9 | 1 | No | Yes |
| 15036209 | ANTIBODIES SPECIFIC TO FCRN | May 2016 | December 2018 | Allow | 31 | 1 | 1 | Yes | No |
| 14886978 | ANTIBODY DERIVATIVES | October 2015 | September 2018 | Allow | 35 | 1 | 1 | Yes | No |
| 14824751 | HUMANIZED ANTI-CD22 ANTIBODY | August 2015 | September 2016 | Allow | 13 | 1 | 2 | Yes | No |
| 14295579 | Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use Thereof | June 2014 | April 2017 | Allow | 35 | 0 | 1 | Yes | No |
| 14211604 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 AND/OR IL-17 | March 2014 | March 2015 | Allow | 12 | 0 | 1 | Yes | No |
| 14195885 | ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIES | March 2014 | April 2016 | Allow | 26 | 1 | 1 | Yes | No |
| 13851625 | Antibodies | March 2013 | June 2014 | Allow | 15 | 0 | 0 | No | No |
| 13846188 | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT FC REGIONS AND METHODS OF USING SAME | March 2013 | September 2014 | Allow | 18 | 1 | 1 | Yes | No |
| 13772063 | HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOF | February 2013 | July 2016 | Allow | 41 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAHLE, CHUN WU.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 15.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DAHLE, CHUN WU works in Art Unit 1641 and has examined 151 patent applications in our dataset. With an allowance rate of 72.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner DAHLE, CHUN WU's allowance rate of 72.2% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by DAHLE, CHUN WU receive 1.99 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DAHLE, CHUN WU is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +41.3% benefit to allowance rate for applications examined by DAHLE, CHUN WU. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 30.8% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 60.5% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 13.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.